More Research Needed to Validate Cannabis for Routine IBD Treatment, Authors Contend

More Research Needed to Validate Cannabis for Routine IBD Treatment, Authors Contend
Cannabis use should be reserved for the control of symptoms in patients with severe inflammatory bowel disease (IBD) that does not respond to current standard of care, according to an article published in the Journal of Gastroenterology & Hepatology Cannabis is used for therapeutic purposes by a significant proportion of IBD patients to relieve the symptoms of the disease such as pain, nausea and loss of appetite. However, the safety profile of cannabis has still not been clearly established and clinical trials have failed to demonstrate that its use is effective in improving the levels of endoscopy, biopsy and inflammatory markers. “It has yet to be determined in human populations whether cannabinoids have therapeutic anti-inflammatory effects in IBD or are simply masking its many debilitating symptoms,” the authors of the article titled “Therapeutic Use of Cannabis in Inflammatory Bowel Disease” wrote. Moreover, there have been concerns about the possible fibrosis-causing effects of cannabis, which need further investigation because fibrosis could have detrimental consequences in patients with diseases causing the narrowing of the bowel, such as IBD. Other adverse side effects of cannabis use include anxiety, panic, psychosis and tachycardia. On the other hand, current options to manage IBD, such as corticosteroids, immunomodulators and biologic agents, could have long-term side effects, including the development of infections and even cancer. Finally, there are concerns about the legality and prepar
Subscribe or to access all post and page content.


  1. Cadlen Leroy says:

    HI, nice information about IBD Treatment. The ultimate goal of clinical treatment of IBD is to obtain complete disease control and to stop disease progression. This includes remission of disease without use of steroids or opiates, normalization of inflammatory markers in the blood, and also the healing of the mucosal lining of the gastrointestinal tract, which typically leads to better clinical outcomes, reduced healthcare costs, and an improved quality of life. Some Pharmaceutical company like Vitality has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol to the gastrointestinal tract. Thanks for sharing.

  2. Bart says:

    “These trials should be placebo-controlled and randomized where neither the participants nor the clinicians know who is getting cannabis and who is getting a placebo.”

    A few months ago I was offered to participate in one of these randomized trials. The catch was that I was to endure two colonoscopies (just having had one the month before) and had a 50-50 chance of getting a placebo. I declined, and asked whether I might try the pills anyway, but that option was not available.

    I understand the science behind these controlled randomized trials, but would it not help to have a few long long-suffering patients try the drugs and report their experience?

Leave a Comment

Your email address will not be published. Required fields are marked *